Abeona Therapeut Stock Price, News & Analysis

Abeona Therapeutics (Nasdaq: ABEO) announced that Beacon Therapeutics has exercised its option to license Abeona's patented AAV204 capsid for potential gene therapies targeting retinal diseases. The worldwide, non-exclusive license follows their July 2024 evaluation agreement.

The AAV204 capsid, from the AIM™ capsid library licensed from the University of North Carolina at Chapel Hill, has demonstrated high macular and optic nerve transduction levels after para-retinal administration and can facilitate transduction of both inner and outer retina after intravitreal administration in mice and non-human primates.

Under the agreement, Beacon can use AAV204 for up to five gene or ophthalmology disease targets. Abeona will receive an undisclosed upfront license payment, potential development, regulatory, and sales milestone payments, and tiered royalties on worldwide net sales of licensed products incorporating AAV204.

Abeona Therapeutics (Nasdaq: ABEO) announced the granting of equity awards to 21 new non-executive employees. The Compensation Committee approved restricted stock awards totaling 48,715 shares of common stock as employment inducements. The shares will vest in three equal annual installments, with full vesting occurring on the third anniversary of the Grant Date, contingent on continued employment.

These equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for inducement grants to new employees outside of shareholder-approved equity plans.

Abeona Therapeutics (Nasdaq: ABEO) has been added to both the Russell 2000® Index and the Russell 3000® Index as part of the indexes' annual reconstitution, effective June 30, 2025. This inclusion follows the recent FDA approval of the company's product ZEVASKYN™.

The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. Membership in these indexes is reviewed annually and maintains for one year.

Abeona Therapeutics (Nasdaq: ABEO) announced the publication of Phase 3 VIITAL study results in The Lancet for ZEVASKYN™, their FDA-approved gene therapy for treating RDEB wounds. The study demonstrated significant efficacy with 81% of treated wounds showing ≥50% healing compared to 16% in control wounds after 24 weeks.

The trial involved 11 patients with 43 pairs of large chronic wounds. Key results showed 65% of treated wounds achieved ≥75% healing versus 7% of control wounds. Patients experienced significant pain reduction (-3.1 in treated vs -0.9 in control wounds). The therapy demonstrated a favorable safety profile with no serious treatment-related adverse events.

ZEVASKYN is the first and only FDA-approved autologous cell-based gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB) wounds. The company expects to treat its first commercial patient in Q3 2025.

Abeona Therapeutics (NASDAQ: ABEO) has granted equity awards to five new non-executive employees as inducement for their employment. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), consist of 11,500 restricted shares of Abeona common stock. The vesting schedule spans three years, with one-third of the shares vesting annually on the grant date anniversary (May 31, 2025). Full vesting will occur on the third anniversary, contingent on continued employment with Abeona.

Abeona Therapeutics (NASDAQ: ABEO) announced that CEO Vish Seshadri and CCO Madhav Vasanthavada will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 11:40 a.m. Eastern Time. Investors can access the live webcast through the company's investor relations website, and a replay will be available for 30 days following the event.

Abeona Therapeutics (NASDAQ: ABEO) reported Q1 2025 financial results and major milestones. The company received FDA approval for ZEVASKYN™, the first autologous cell-based gene therapy for treating RDEB wounds. Following approval, Abeona activated its first qualified treatment center at Lurie Children's Hospital, with the first patient expected in Q3 2025. The company entered into a sales agreement for its priority review voucher for $155 million. Financial highlights include: cash position of $84.5 million as of March 31, 2025, Q1 net loss of $12.0 million ($0.24 per share), and R&D expenses of $9.9 million. Notably, about 30 patients have started registering in the Abeona Assist program, and the company has secured value-based agreements with payers covering approximately 100 million commercially-insured lives.

Abeona Therapeutics (NASDAQ: ABEO) and Lurie Children's Hospital announced the activation of the first Qualified Treatment Center (QTC) for ZEVASKYN, a groundbreaking gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN, recently FDA-approved on April 29, 2025, is the first and only autologous cell-based gene therapy for RDEB wounds treatment with a single application.

Lurie Children's, a top-ranked hospital caring for over 150 epidermolysis bullosa patients, will begin patient identification with treatments expected to start in Q3 2025. The first patient is scheduled for biopsy in July 2025 and treatment in August 2025. To support patient access, Abeona has launched Abeona Assist, a comprehensive support program offering insurance benefits guidance, financial assistance, and travel logistics support.

Abeona Therapeutics announced that Ann & Robert H. Lurie Children's Hospital of Chicago has become the first Qualified Treatment Center for ZEVASKYN, their newly FDA-approved gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB) wounds. ZEVASKYN, approved on April 29, 2025, is the first and only autologous cell-based gene therapy for RDEB wounds treatment with a single application. Lurie Children's, a top-ranked hospital caring for over 150 EB patients, expects to begin treatments in Q3 2025, with the first patient scheduled for biopsy in July 2025. The hospital has been offering FDA-approved gene therapies since 2019, and ZEVASKYN will be their tenth gene therapy treatment. Abeona has launched Abeona Assist™, a comprehensive patient support program offering insurance benefits guidance and logistical assistance for eligible patients.